Cancer Research Technology
Log in Register
Menu

Anti-Neuroblastoma [FMG25]

Invented by Dr JOHN KEMSHEAD from SHIRE PHARMACEUTICALS
Invented at Imperial Cancer Research Fund

Info

Catalogue Number 151730
Applications FACS
Antigen/Gene or Protein Targets Human Neuroblastoma
Reactivity Human
Relevance Useful diagnostic reagent to differentiate between neuroblastoma and rhabdomyosarcoma. May be useful as one of a panel of reagents to detect and remove tumour cells from bone marrow harvested for autologous transplantation. Also cross reacts with normal brain and peripheral nerve. The antibody does not bind to other small round-cell tumours of childhood.
Host Mouse
Immunogen Human cutaneous T cell lymphoma (HUT 78), SPF female Balb/c mice were injected i.p with 2 x 10*5 cells in complete Freund's adjuvant. 30 days later a 2nd i.p injection of 2 x 10*5 cells without adjuvant was given. Fusion was 5 days
Subclass IgG1
Myeloma Used P3X63Ag8
Strain Balb/c
Research Area Cancer, Cell Type or Organelle Marker

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Gibson et al. 1987. Int J Cancer. 39(5):554-9. PMID: 3494688.

A monoclonal antibody (FMG25) that can differentiate neuroblastoma from other small round-cell tumours of childhood.

Europe PMC ID: 3494688


Add a reference

References: 2 entries

Gibson et al. 1987. Int J Cancer. 39(5):554-9. PMID: 3494688.

A monoclonal antibody (FMG25) that can differentiate neuroblastoma from other small round-cell tumours of childhood.


Add a reference